MX2022005292A - Metodos de tratamiento con anticuerpos contra bcma y cd3. - Google Patents

Metodos de tratamiento con anticuerpos contra bcma y cd3.

Info

Publication number
MX2022005292A
MX2022005292A MX2022005292A MX2022005292A MX2022005292A MX 2022005292 A MX2022005292 A MX 2022005292A MX 2022005292 A MX2022005292 A MX 2022005292A MX 2022005292 A MX2022005292 A MX 2022005292A MX 2022005292 A MX2022005292 A MX 2022005292A
Authority
MX
Mexico
Prior art keywords
methods
bcma
treatment
antibodies against
against bcma
Prior art date
Application number
MX2022005292A
Other languages
English (en)
Spanish (es)
Inventor
Michael Burgess
Minh Diem Vu
Kristen Hege
Kaushik Datta
Isaac Boss
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2022005292A publication Critical patent/MX2022005292A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2022005292A 2019-11-05 2020-11-04 Metodos de tratamiento con anticuerpos contra bcma y cd3. MX2022005292A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19207293 2019-11-05
EP20179573 2020-06-11
PCT/US2020/058939 WO2021092056A1 (en) 2019-11-05 2020-11-04 Methods of treatment with antibodies against bcma and cd3

Publications (1)

Publication Number Publication Date
MX2022005292A true MX2022005292A (es) 2022-08-10

Family

ID=75849140

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005292A MX2022005292A (es) 2019-11-05 2020-11-04 Metodos de tratamiento con anticuerpos contra bcma y cd3.

Country Status (11)

Country Link
US (1) US20230057602A1 (cg-RX-API-DMAC7.html)
EP (1) EP4054725A4 (cg-RX-API-DMAC7.html)
JP (1) JP7792333B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220093141A (cg-RX-API-DMAC7.html)
CN (1) CN115279459A (cg-RX-API-DMAC7.html)
AU (1) AU2020379757A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022008516A2 (cg-RX-API-DMAC7.html)
CA (1) CA3160137A1 (cg-RX-API-DMAC7.html)
IL (1) IL292704A (cg-RX-API-DMAC7.html)
MX (1) MX2022005292A (cg-RX-API-DMAC7.html)
WO (1) WO2021092056A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
CA2992797A1 (en) 2015-08-03 2017-02-09 Engmab Sarl Monoclonal antibodies against bcma
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
HUE068401T2 (hu) 2019-11-11 2024-12-28 Amgen Res Munich Gmbh A BCMA elleni hatóanyagok adagolási rendje
BR112023027006A2 (pt) * 2021-06-21 2024-03-12 BioNTech SE Método para reduzir ou prevenir a progressão de um tumor ou tratar um câncer em um sujeito, e, agente de ligação
CN115521381B (zh) * 2021-06-24 2024-10-29 益科思特(北京)医药科技发展有限公司 结合bcma和cd3的双特异性抗体及其制备方法与应用
KR20260057078A (ko) * 2023-08-18 2026-04-27 브리스톨-마이어스 스큅 컴퍼니 Bcma 및 cd3에 결합하는 항체를 포함하는 조성물 및 치료 방법
EP4777540A1 (en) 2023-09-13 2026-07-22 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
AU2024390850A1 (en) * 2023-12-01 2026-04-02 Teneoone, Inc. Methods for the treatment of multiple myeloma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009299794B2 (en) * 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
EP2762497A1 (en) * 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
CA2992797A1 (en) * 2015-08-03 2017-02-09 Engmab Sarl Monoclonal antibodies against bcma
US11124577B2 (en) * 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
EP3541843A1 (en) * 2016-11-15 2019-09-25 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies

Also Published As

Publication number Publication date
AU2020379757A1 (en) 2022-05-26
BR112022008516A2 (pt) 2022-08-30
KR20220093141A (ko) 2022-07-05
IL292704A (en) 2022-07-01
EP4054725A4 (en) 2024-01-10
CA3160137A1 (en) 2021-05-14
CN115279459A (zh) 2022-11-01
JP7792333B2 (ja) 2025-12-25
WO2021092056A1 (en) 2021-05-14
JP2022553822A (ja) 2022-12-26
EP4054725A1 (en) 2022-09-14
US20230057602A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
BR112022008516A2 (pt) Métodos de tratamento com anticorpos contra bcma e cd3
BR112021023026A2 (pt) Moléculas de ligação biespecíficas anti-ror1/anti-cd3
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
MX2021002970A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor.
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CO2018001485A2 (es) Diacuerpos monovalentes biespecificos que son capaces de unirse a b7 - h3 y cd3
PE20190392A1 (es) Antianticuerpos gprc5d, moleculas de union al antigeno biespecificas que se unen a gprc5d y cd3, y usos de estas
CO2018001524A2 (es) Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estos
MX2019010156A (es) Proteínas multiespecíficas de unión de direccionamiento a anhidrasa carbónica 9 (caix), anoctamina-1 (ano1), mesotelina, antígeno de superficie celular de trofoblasto (trop2), antígeno carcinoembrionario (cea) o claudina-18.2.
NI201800057A (es) Anticuerpos anti-il1rap, moléculas de unión de antígeno biespecíficas que se unen a il1rap y cd3, y sus usos.
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
MX381046B (es) Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.
CO2020001981A2 (es) Proteínas que se unen a nkg2d, cd16 y flt3
NI201700025A (es) Agentes de unión a cd123 y usos de estos.
MX375746B (es) Combinación de lenalidomida y constructo de polipéptido, y sus usos.
MY202368A (en) Methods of treating ulcerative colitis
MX2018012468A (es) Construcciones de union a antigeno multiespecificas dirigidas a agentes inmunoterapeuticos.
CL2015002223A1 (es) Objetivo terapéutico y diagnostico.
MX2017001031A (es) Móleculas de unión a her2 y cd3 biespecíficas.
CO2018001621A2 (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
CL2019001198A1 (es) Anticuerpo bioespecífico contra bcma y cd3 y un fármaco inmunológico para uso combinado en el tratamiento de mieloma múltiple.
MX392014B (es) Composiciones y métodos para modular la expresión de angiotensinógeno.
MX2018000347A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
MX2025003354A (es) Anticuerpos que se unen a 5t4
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.